Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Genome sequencing as a prognostic tool

Richard Rosenquist • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia

Richard Rosenquist, MD, PhD, Karolinska University Hospital, Solna, Sweden, discusses the role of genomics as a prognostic and predictive tool in cancer treatment and outlines some of the techniques currently employed. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Richard Rosenquist

The advancements and remaining challenges in precision medicine for CLL 2:09
The advancements and remaining challenges in precision medicine for CLL
Richard Rosenquist • 27 Sep 2024
Recommendations for biomarker analysis in CLL: updates from ERIC 2024 5:40
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
Richard Rosenquist • 27 Sep 2024
The impact of IGHV mutational status in treatment decisions in CLL 1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
Common genetic tests in CLL & when these tests should be performed 1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals